LEADER 04388nam 22006015 450 001 9910733727803321 005 20200706201612.0 010 $a3-319-13081-1 024 7 $a10.1007/978-3-319-13081-1 035 $a(CKB)3710000000372121 035 $a(EBL)1997866 035 $a(OCoLC)904597987 035 $a(SSID)ssj0001465000 035 $a(PQKBManifestationID)11902199 035 $a(PQKBTitleCode)TC0001465000 035 $a(PQKBWorkID)11458503 035 $a(PQKB)10125618 035 $a(DE-He213)978-3-319-13081-1 035 $a(MiAaPQ)EBC1997866 035 $a(PPN)184890306 035 $a(EXLCZ)993710000000372121 100 $a20150305d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntibody-Drug Conjugates $eThe 21st Century Magic Bullets for Cancer /$fedited by Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro 205 $a1st ed. 2015. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015. 215 $a1 online resource (248 p.) 225 1 $aAAPS Advances in the Pharmaceutical Sciences Series,$x2210-7371 ;$v17 300 $aDescription based upon print version of record. 311 $a3-319-13080-3 320 $aIncludes bibliographical references and index at the end of each chapters. 327 $a1 Antibody-Drug Conjugates: A Historical Review -- 2 Payloads of Antibody-Drug Conjugates -- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy -- 4 Linker Design for Antibody-Drug Conjugates -- 5 Formulation Development for Antibody-Drug Conjugates -- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates -- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates -- 8 Regulatory Considerations -- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy -- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal -- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate -- 12 Ado-Trastuzumab Emtansine -- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer -- 14 Summary and Future Directions. 330 $aThis authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field. 410 0$aAAPS Advances in the Pharmaceutical Sciences Series,$x2210-7371 ;$v17 606 $aPharmaceutical technology 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 615 0$aPharmaceutical technology. 615 14$aPharmaceutical Sciences/Technology. 676 $a615.36 702 $aWang$b Jeffrey$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aShen$b Wei-Chiang$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aZaro$b Jennica L$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910733727803321 996 $aAntibody-drug conjugates$92231062 997 $aUNINA